Recent developments in cathepsin K inhibitor design

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 5, 2005, Pages 619-630

  Grabowska, Urszula B ^a   Chambers, Timothy J ^b   Shiroo, Masahiro ^a  

^a MEDIVIR AB   (Sweden)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bone resorption; Cathepsin K; Cysteine protease; Osteoporosis; Reversible protease inhibitor

Indexed keywords

AFG 495; BALICATIB; CATHEPSIN K; CATHEPSIN K INHIBITOR; CRA 013783; RELACATIB; SB 357114; UNCLASSIFIED DRUG;

BONE DEFECT; BONE DENSITY; BONE STRENGTH; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

ANIMALS; BONE RESORPTION; CATHEPSINS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; OSTEOPOROSIS;

EID: 24044436528     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Chambers TJ: The pathobiology of the osteoclast. J Clin Pathol (1985) 38(3):241-252.
2. Raisz LG: Physiology and pathophysiology of bone remodeling. Clin Chem (1999) 45(8 Pt 2):1353-1358.
3. Xing L, Boyce BF: Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun (2005) 328(3):709-720.
4. Manolagas SC: Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev (2000) 21(2):115-137. Provides a comprehensive review of the molecular mechanisms of bone metabolism.
5. Estrogen and estrogen with progestin therapies for postmenopausal women: US Food and Drug Administration, Rockville, MD, USA (2005). http://www.fda.gov/ cder/drug/infopage/estrogens_progestins/default.htm
6. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H: Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res (2004) 19(6):999-1005.
7. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY: Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab (2005) 90(3):1294-1301. Provides a caution about the potential development of excessive suppression of bone turnover during long-term use of alendronate.
8. Ott SM: Long-term safety of bisphosphonates. J Clin Endocrinol Metab (2005) 90(3):1897-1899. Editorial comment on the article reported in reference [7].
9. Osteogenesis Imperfecta Foundation: Biphosphonates - an information update from the OI Foundation's Medical Advisory Council: The Osteogenesis Imperfecta Foundation, Gaithersburg, MD, USA (2004). http://www.oif.org/site/ DocServer?doclD=803
10. Robinson NA, Yeo JF: Bisphosphonates - a word of caution. Ann Acad Med Singapore (2004) 33(4 Suppl):48-49. Comments on a possible association between avascular necrosis of the jaw and bisphosphonate treatment.
11. Green JR: Bisphosphonates: Preclinical review. Oncologist (2004) 9(Suppl 4):3-13. Provides a useful summary of the mechanism of action of bisphosphonates.
12. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J et al: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res (1997) 12(10):1700-1707.
13. Rousselle AV, Heymann D: Osteoclastic acidification pathways during bone resorption. Bone (2002) 30(4):533-540.
14. Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, Hakeda Y, Kumegawa M: Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem (1994) 269(2):1106-1109.
15. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T: Molecular cloning of human cDNA for cathepsin K: Novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun (1995) 206(1):89-96.
16. Shi GP, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ: Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett (1995) 357(2):129-134.
17. Gelb BD, Shi GP, Chapman HA, Desnick RJ: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science (1996) 273(5279):1236-1238. Discusses how genetic analysis of pycnodysostosis reveals a link between the disease and cathepsin K.
18. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA (1998) 95(23):13453-13458. Provides evidence that bone resorption is severely impaired in cathepsin K knockout mice, thus confirming the genetic link between cathepsin K and pycnodysostosis.
19. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P et al: Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res (1999) 14(10):1654-1663. Suggests that the use of cathepsin K inhibitors for osteoporosis therapy is advantageous due to osteoclast-specific localization.
20. Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J: Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res (2001) 16(8):1444-1452. Reports that bone formation and turnover rates are higher in cathepsin K transgenic mice compared with healthy animals, suggesting close interactions between osteoclast and osteoblast cells.
21. Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh HJ, Erhard KF, Davis LD, Tomaszek TA, Tew D, Salyers K et al: Azepanone-based inhibitors of human and rat cathepsin K. J Med Chem (2001) 44(9):1380-1395. Discusses the introduction of a conformational constraint to increase inhibitor potency.
22. Kung Sutherland MS, Lipps SG, Patnaik N, Gayo-Fung LM, Khammungkune S, Xie W, Brady HA, Barbosa MS, Anderson DW, Stein B: SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: Role of IL-6 and GM-CSF. Cytokine (2003) 23(1-2):1-14.
23. Sarma U, Edwards M, Motoyoshi K, Flanagan AM: Inhibition of bone resorption by 17β-estradiol in human bone marrow cultures. J Cell Physiol (1998) 175(1):99-108.
24. Susa M, Luong-Nguyen N-H, Cappellen D, Zamurovic N, Gamse R: Human primary osteoclasts: In vitro generation and applications as pharmacological and clinical assay. J Transl Med (2004) 2(1):6. Reports the use of dexamethasone for the improved differentiation of human peripheral blood mononuclear cells to osteoclasts. The previously reported M-CSF, RANKL and TGFβ were also used.
25. Massey HM, Scopes J, Horton MA, Flanagan AM: Transforming growth factor-β1 (TGF-β) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment. Bone (2001) 28(6):577-582.
26. Fox SW, Hague J, Lovibond AC, Chambers TJ: The possible role of TGF-β-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol (2003) 170(7):3679-3687. Describes how TGFβ primes osteoclast precursor cells by suppressing the signals through inhibitory cytokines such as IFNβ.
27. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF et al: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature (2002) 416(6882):744-749. Results suggest that IFNβ oppose the RANKL-mediated differentiation of osteoclasts to maintain bone mass.
28. Falgueyret J-P, Black WC, Cromlisrv W, Desmarais S, Lamontagne S, Mellon C, Riendeau D, Rodan S, Tawa P, Wesolowski G, Bass KE et al: An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal Biochem (2004) 335(2):218-227. Reports the use of a novel diazomethylketone-containing irreversible inhibitor for detecting catalytically active cathepsins B, L, K and S.
29. Barrett AJ, Kembhavi AA, Hanada K: E-64 [L-trans-epoxysuccinyl-leucyl- amido(4-guanidino)butane] and related epoxides as inhibitors of cysteine proteinases. Acta Biol Med Ger (1981) 40(10-11):1513-1517.
30. Greenbaum D, Medzihradszky KF, Burlingame A, Bogyo M: Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol (2000) 7(8):569-581.
31. McQueney MS, Feild J, Hanning CR, Brun K, Ramachandran K, Connor J, Drake F, Jones CS, Amegadzie BY: Cynomolgus monkey (Macaca fascicularis) cathepsin K: Cloning, expression, purification and activation. Protein Expr Purif (1998) 14(3):387-394.
32. Guay J, Riendeau D, Mancini JA: Cloning and expression of rhesus monkey cathepsin K. Bone (1999) 25(2):205-209.
33. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y et al: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res (2001) 16(10):1739-1746. Demonstrates the feasibility of a primate chemically induced OVX model to evaluate cathepsin K inhibitors by monitoring telopeptides as biomarkers of bone resorption.
34. Bowles EA, Weaver DS, Telewski FW, Wakefield AH, Jaffe MJ, Miller LC: Bone measurement by enhanced contrast image analysis: Ovariectomized and intact Macaca fascicularis as a model for human postmenopausal osteoporosis. Am J Phys Anthropol (1985) 67(2):99-103.
35. Jerome CP, Carlson CS, Register TC, Bain FT, Jayo MJ, Weaver DS, Adams MR: Bone functional changes in intact, ovariectomized, and ovariectomized, hormone-supplemented adult cynomolgus monkeys (Macaca fascicularis) evaluated by serum markers and dynamic histomorphometry. J Bone Miner Res (1994) 9(4):527-540.
36. Kasra M, Grynpas MD: Effect of long-term ovariectomy on bone mechanical properties in young female cynomolgus monkeys. Bone (1994) 15(5):557-561.
37. Yamashita DS, Dodds RA: Cathepsin K and the design of inhibitors of cathepsin K. Curr Pharm Des (2000) 6(1):1-24.
38. Marquis RW: Inhibition of the cysteine protease cathepsin K (EC 3.4.22.38). Ann Rep Med Chem (2004) 39:79-98.
39. Yasuda Y, Kaleta J, Bromme D: The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics. Adv Drug Deliv Rev (2005) 57(7):973-993.
40. Veber DF, Thompson SK: The therapeutic potential of advances in cysteine protease inhibitor design. Curr Opin Drug Discovery Dev (2000) 3(4):362-369.
41. Deaton DN, Kumar S: Cathepsin K inhibitors: Their potential as antiosteoporosis agents. Prog Med Chem (2004) 42:245-375.
42. McKerrow JH: Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: Insights on safety, target validation and mechanism of action. Int J Parasitol (1999) 29(6):833-837.
43. Kim TS, Hague AB, Lee TI, Lian B, Tegley CM, Wang X, Burgess TL, Qian YX, Ross S, Tagari P, Lin CH et al: (4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors. Bioorg Med Chem Lett (2004) 14(1):87-90.
44. 1′ substituents. Bioorg Med Chem Lett (2003) 13(12):1997-2001.
45. Altmann E, Renaud J, Green J, Parley D, Cutting B, Jahnke W: Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. J Med Chem (2002) 45(12):2352-2354.
46. Schechter I, Berger A: On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 27(2):157-162.
47. Smyth TP: Substrate variants versus transition state analogues as noncovalent, reversible enzyme inhibitors. Bioorg Med Chem (2004) 12(15):4081-4088. Discusses the use of transition state analogs as non-covalent and reversible inhibitors.
48. Lucas EC, Williams A: The pH dependencies of individual rate constants in papain-catalyzed reactions. Biochemistry (1969) 8(12):5125-5135.
49. Palmer JT: Design, synthesis and in vivo biology of potent, selective cathepsin K inhibitors as potential osteoporosis therapeutics. IBC's Protease Inhibitors, San Diego, USA (2004).
50. Robichaud J, Oballa R, Prasit P, Falgueyret J-P, Percival MD, Wesolowski G, Rodan SB, Kimmel D, Johnson C, Bryant C, Venkatraman S et al: A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J Med Chem (2003) 46(17):3709-3727.
51. Robichaud J, Bayly C, Oballa R, Prasit P, Mellon C, Falgueyret J-P, Percival MD, Wesolowski G, Rodan SB: Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. Bioorg Med Chem Lett(2004) 14(16):4291-4295.
52. DeVito SC, Pearlman RS: Physicochemical and structural factors influencing cyanide release from nitriles. Med Chem Res (1992) 1:461-465.
53. Altmann E, Cowan-Jacob SW, Missbach M: Novel purl ne nitrile derived inhibitors of the cysteine protease cathepsin K. J Med Chem (2004) 47(24):5833-5836. Reports a high-throughput screening hit that leads to a novel purine-based inhibitor containing no amide bonds.
54. Barrett DG, Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Willard DH Jr, Wright LL: Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett (2005) 15(12):3039-3043.
55. Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Tavares FX, Willard DH, Wright LL: Novel and potent cyclic cyanamide-based cathepsin K inhibitors. Bioorg Med Chem Lett (2005) 15(7):1815-1819.
56. Catalano JG, Deaton DN, Furfine ES, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Willard DH Jr, Wright LL: Exploration of the P1 SAR of aldehyde cathepsin K inhibitors. Bioorg Med Chem Lett (2004) 14(1):275-278.
57. Boros EE, Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Paulick MG, Shewchuk LM, Thompson JB, Willard DH Jr, Wright LL: Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors. Bioorg Med Chem Lett (2004) 14(13):3425-3429.
58. Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH Jr et al: Design of potent, selective and orally bioavailable inhibitors of cysteine protease cathepsin K. J Med Chem (2004) 47(3):588-599.
59. Tavares FX, Deaton DN, Miller LR, Wright LL: Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications. J Med Chem (2004) 47(21):5057-5068.
60. Tavares FX, Deaton DN, Miller AB, Miller LR, Wright LL, Zhou HQ: Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K. J Med Chem (2004) 47(21):5049-5056.
61. Barrett DG, Catalano JG, Deaton DN, Long ST, Miller LR, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ: Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett (2004) 14(10):2543-2546.
62. Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller LR, Payne JA, Wells-Knecht KJ, Wright LL: Design of small molecule ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett (2004) 14(3):719-722.
63. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Shewchuk LM, Wells-Knecht KJ, Willard DH Jr, Wright LL: Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1′, P1 and/or P3 substitutions. Bioorg Med Chem Lett (2004) 14(19):4897-4902.
64. Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Wells-Knecht KJ, Wright LL: A structural screening approach to ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett (2005) 15(9):2209-2213.
65. Marquis RW, Ru Y, Zeng J, Trout RE, LoCastro SM, Gribble AD, Witherington J, Fenwick AE, Gamier B, Tomaszek T, Tew D et al: Cyclic ketone inhibitors of the cysteine protease cathepsin K. J Med Chem (2001) 44(5):725-736.
66. Marquis RW, Ward KW, Roethke T, Smith BR, Ru Y, Yamashita DS, Tomaszek TA, Gorycki PD, Cheng H-Y, James IE, Stroup GB et al: An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey. Mol Pharm (2004) 1(1):97-100.
67. Watts J, Benn A, Flinn N, Monk T, Ramjee M, Ray P, Wang Y, Quibell M: Functionalised 2,3-dimethyl-3-aminotetrahydrofuran-4-one and N-(3-oxo-hexahydrocyclopenta[b]furan-3a-yl)acylamide based scaffolds: Synthesis and cysteinyl proteinase inhibition. Bioorg Med Chem (2004) 12(11):2903-2925.
68. Setti EL, Davis D, Jane JW, Jeffery DA, Cheung H, Yu W: 3,4-Disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity. Bioorg Med Chem Lett (2005) 15(5):1529-1534.
69. Quibell M, Benn A, Flinn N, Monk T, Ramjee M, Wang Y, Watts J: Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b] pyridin-3-one based scaffolds: Synthesis and cysteinyl proteinase inhibition. Bioorg Med Chem (2004) 12(21):5689-5710.
70. Quibell M, Benn A, Flinn N, Monk T, Ramjee M, Ray P, Wang Y, Watts J: Synthesis and evaluation of cis-hexahydropyrrolo[3,2-b]pyrrol-3-one peptidomimetic inhibitors of CAC1 cysteinyl proteinases. Bioorg Med Chem (2005) 13(3):609-625.
71. Wang Y, Benn A, Flinn N, Monk T, Ramjee M, Watts J, Quibell M: cis-6-Oxohexahydro-2-oxa-1,4-diazapentalene and cis-6-oxo-hexa-hydropyrrolo[3,2- c]pyrazole based scaffolds: Design rationale, synthesis and cysteinyl proteinase inhibition. Bioorg Med Chem Lett (2005) 15(5):1327-1331.
72. Berdowska I: Cysteine proteases as disease markers. Clin Chim Acta (2004) 342(1-2):41-69.
73. Grosios K, Altmann E, Gasser JA, Stumm M, Zimmermann J: Efficacy of the bisphosphonate Zometa® and the selective cathepsin K inhibitor AFG495 administered alone or in combination in a murine xenograft model of breast cancer cell induced osteolysis. 96th American Association for Cancer Research Meeting, Anaheim, CA, USA (2005):Abs 2910.